AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01883895 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Forgionei-Barber pressure-pain stimulator
Description: Pain testing will be conducted using a Forgioni-Barber pressure-pain stimulator to deliver 3000-gm force to the middle digit of the non-dominant middle finger for up to 120 seconds. During stimulation, subjects will press a button attached to a timer when the pressure stimulus first becomes painful (pain threshold) and will also rate their perceived pain intensity using a 0-100 numeric pain rating scale at 20 second intervals during the 2 minute exposure to the pressure stimulus. This validated protocol has been used in previous research by investigators in this study. This will be used for both exercise sessions and the control session. Forgionei-Barber pressure-pain stimulator will be used.
Study NCT01883895 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Concentric Exercise
Description: Concentric testing will utilize a dumbbell with elbow flexion exercise. Subjects will perform 5 sets of 20 reps at 30% MVC. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
Study NCT01883895 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: isometric exercise
Description: When undergoing isometric exercise, subjects will perform 5 sets of sustained muscle contraction for 65 seconds using a hand-grip dynamometer. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
Study NCT02171000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS
Description: 150 mg capsules, b.i.d, 7 days
Study NCT01053455 — intervention group
Intervention type: DEVICE
Intervention: SiPAP
Description: biphasic CPAP (SiPAP) to be alternated in 1 hour blocks with NCPAP
Study NCT00483535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW273225
Description: GW273225 will be available as 25 milligram tablets.
Study NCT00483535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COC
Description: COC will consist of Microgynon 30 which is available as ethinylestradiol 30 micrograms/levonorgestrel 150 micrograms beige color, sugar-coated tablets.
Study NCT02785198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive knee extensor machine
Description: The passive training machine, moves both legs from flexion to extension and back, 60 times per minute in 1 hour, 3 times per week. ROM is 60 degrees
Study NCT00973258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Each subject in the nutritional intervention group is provided with a commercial liquid formula (Fortisip Multi Fibre, Nutricia), which should be taken every evening for a period of 24 weeks. Subjects are also given one capsule of iron and folate supplement (Sangobion, Merck; consisting of 1 mg folate and 29mg iron), one capsule of Vitamin B6 and vitamin B12 supplement (Neuroforte; consisting of 200mcg B12 and 200mg vit B6) and one tablet of Caltrate with Vitamin D (consisting of 200 IU vitamin D and 600 mg of calcium) for a duration of 24 weeks.
Study NCT00973258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The exercise intervention group comprises a combination of 2 types of exercise: resistance exercise and in-balance exercise. Key components in both programs are balance and strength, because these are the most prominent domains that should be addressed in at risk frail elderly. The first program is administered in the first 6-week, and then followed by the second program for the next 6-week of intervention period. Both exercise programmes are tailored to the functional needs of the participants, maintaining a moderate intensity that focuses on long-term sustainability and enjoyment.
Study NCT00973258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: The proposed cognitive training intervention program comprises:~1. Reasoning training focusing on inductive reasoning, the ability to solve problems that follow a serial pattern and manifest in executive functioning.~2. Memory training focusing on verbal episodic memory, which deals with acquisition and retrieval of information acquired in a particular place at a particular time.~3. Speed training focusing on visual search and the ability to identify and locate visual information quickly in a divided attention format, with and without distractors.
Study NCT00973258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined
Description: Nutritional Intervention + Physical Exercise + Cognitive Training
Study NCT00973258 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive their usual diet and placeboes.
Study NCT03308552 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: SIB-IMRT
Description: PTV:50.4Gy/28f, PGTV:59.92Gy/28f
Study NCT03308552 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SIB-IMRT
Description: PTV:50.4Gy/28f, PGTV:59.92Gy/28f
Study NCT03308552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 45-50 mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
Study NCT03308552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-Based Drug
Description: Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
Study NCT03308552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 150mg/m2 on day1,every 3 weeks, 4 cycles, 1-3 months after completion of radiotherapy
Study NCT03308552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 150mg/m2 on day1,every 3 weeks, 4 cycles, 1-3 months after completion of radiotherapy
Study NCT03308552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Platinum-Based Drug
Description: Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin 50mg on day 1),every 3 weeks, 4 cycles, 1 month after completion of radiotherapy
Study NCT04116892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the Fill group
Description: The internal limiting membrane around the MH was left to fill the hole
Study NCT04116892 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the peeling group
Description: the internal limiting membrane was discarded
Study NCT03047395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.
Study NCT00941967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00941967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00941967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally.
Study NCT03262259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GSDG multi-component intervention
Description: Multi-component intervention, including screening and brief intervention, other evidence-based interventions, and novel or partially tested interventions that warrant further evaluation.
Study NCT04296266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alda-341
Description: Dietary supplement d-limonene orally administered as a drug.
Study NCT04182295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: A sterilised stainless steel needle (diameter 0.25mm X length 40mm, Dongbang Acupuncture Inc., Boryeong, Chungchenongnam-do, Korea) will be given at PC3, LI4, LI11, and LU5 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).
Study NCT04182295 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Park Sham Needle
Description: A Park Sham Needle (Meridius Medical Ltd. \& DongBang Acuprime Ltd., Exeter, UK), non-penetrating sham acupuncture, will be given at two points on the belly of biceps brachii, 1 cun proximedially from LI11, and 1 cun laterally from PC3 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).
Study NCT01665131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cameron Health S-ICD SQ-RX
Study NCT00706290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy
Description: The cognitive-behavioral intervention consists of 6-7 sessions lasting 60-90 minutes each focused on psycho-education; relaxation training; cognitive-restructuring and coping with cancer fears; and activity planning and pacing. Sessions are delivered by a licensed clinical psychologist or trained psychology fellow or graduate student.
Study NCT01694316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Neurobehavioral Intervention
Description: Targeted, computerized interventions completed from the participants' own home on a computer.
Study NCT01694316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Neurobehavioral Intervention
Description: Targeted, computerized interventions completed from the participants' own home on a computer.
Study NCT00425464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Monofocal Intraocular Lens
Description: The control (active comparator) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a standard monofocal intraocular lens.~Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis.
Study NCT00425464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synchrony® Dual Optic Intraocular Lens
Description: The Synchrony® Dual Optic Intraocular Lens (experimantal) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a Synchrony® Dual Optic Intraocular Lens.~Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis.
Study NCT01635738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP GMNL-133 capsule
Description: One capsule with 2x10\^9 (cfu) LP GMNL-133, once daily, PO
Study NCT01635738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LF GM-090 capsule
Description: Arm: LF GM-090 group One capsule with 2x10\^9 (cfu) LF GM-090, once daily, PO
Study NCT01635738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP GMNL-133 +LF GM-090 capsule
Description: One capsule with 4x10\^9 (cfu) LP GMNL-133 +LF GM-090, once daily, PO
Study NCT01635738 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02358759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Correction of abnormally fertilized oocytes
Description: Removing of extra developed nucleus from fertilized oocyte.
Study NCT03099564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200mg IV every three weeks
Study NCT03099564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Y90 radioembolization
Description: The first Y90 radioembolization treatment will be administered one week after the first dose of pembrolizumab. If a second Y90 radioembolization treatment is required for bilobar disease, this should occur within 4 weeks of the initial procedure (between Cycles 2 and 3 of pembrolizumab).
Study NCT00682981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax
Description: IV Infusions for 3 consecutive days of either 3-hours, 2 hours duration
Study NCT00682981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/etoposide
Description: Carboplatin/etoposide combination
Study NCT00682981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin/etoposide
Description: Carboplatin/etoposide combination
Study NCT03308552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-Based Drug
Description: Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin 50mg on day 1),every 3 weeks, 4 cycles, 1 month after completion of radiotherapy
Study NCT04270461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKG2D-based CAR T-cells
Description: Autologous genetically modified anti-NKG2DLs CAR transduced T cells
Study NCT04587817 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: camrelizumab+hyperfractionated radiotherapy
Description: Immunotherapy combined with hyperfractionated radiotherapy
Study NCT01581502 — intervention group
Intervention type: OTHER
Intervention: This is an observational study.
Description: This is an observational, not intervention, study.
Study NCT03329859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High resolution standardized laparoscopic cholecystectomy
Description: High resolution standardized laparoscopic cholecystectomy
Study NCT03329859 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High resolution standardized laparoscopic cholecystectomy
Description: High resolution standardized laparoscopic cholecystectomy
Study NCT03303768 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Investigation of relevant ultrasound signs to improve the antenatal diagnosis of coarctation of the aorta by calculating the sensitivity and specificity of these different signs
Study NCT05143398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet + protein
Description: Comparison of the efficacy
Study NCT05143398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet + EAA
Description: Comparison of the efficacy
Study NCT05143398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet + EAA and TCA
Description: Comparison of the efficacy
Study NCT05143398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Comparison of the efficacy
Study NCT01448629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants are using their own product and this procedure is called Standard Care.~Standard Care are the participants own products and may consist of several manufacturer and brand names.
Study NCT01448629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: River
Description: River is a new developed product with Coloplast as manufacturer
Study NCT03231800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasotraline
Description: dasotraline 2mg capsule once daily
Study NCT03231800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily
Study NCT00859222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study NCT00859222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT01162577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Concerns
Description: Standard Quitline plus weight coaching
Study NCT03477773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity exergaming
Description: Perform high-intensity exercise whilst playing a developed exergame. A full warm-up performed prior to the session was performed (\~70% HRmax). Periods of exercise were performed at an intensity >85% HRmax for periods of 10, 20 and 30s, interspersed with periods of rest, for a total of 2-3 minutes per session. Heart rate was monitored throughout the intervention.
Study NCT00596882 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Message Prime
Description: Participants will be randomized to genetic prime messages or threat only message at the time of the intial telephone screen. Following phone screen, all eligibleparticipants will receive 13 weeks of Chantix with smoking cessation counseling.
Study NCT00596882 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Message Prime
Description: Particpants will be randomized into 1 of 2 groups. 1 group will recieve a message detailing the negative helaht consequenes of smoking and the other group will receive this information along with information about the genetic incluences on smoking behavior.
Study NCT02941900 — intervention group
Intervention type: GENETIC
Intervention: MC1R genotyping
Study NCT02941900 — intervention group
Intervention type: BEHAVIORAL
Intervention: MC1R Testing Website
Description: The website includes three educational modules about genetic testing with corresponding knowledge questions.
Study NCT02941900 — intervention group
Intervention type: BEHAVIORAL
Intervention: Baseline Survey
Study NCT03627273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6 minutes walking test with walker
Description: to walk during 6 minutes with walker
Study NCT03627273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 6 minutes walking test
Description: to walk during 6 minutes with walker
Study NCT00693940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group mediated cognitive behavioral (GMCB) sessions
Description: GMCB will include weekly group exercise sessions, lasting approximately 60 to 75 minutes each for a 6 month period. During these sessions, participants will be asked to exercise by walking around a track. There will also be a group discussion, led by a facilitator, who will help participants find ways to increase the frequency of their walking exercise at home. After completing the GMCB sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
Study NCT00693940 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education sessions
Description: Health education will include weekly educational sessions on a health-related topic, lasting approximately 60 minutes each. After completing the health education sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
Study NCT01129102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-01
Description: Norethisterone 1mg, Ethinyl estradiol 0.02mg
Study NCT01129102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IKH-01
Description: Norethisterone 1mg, Ethinyl estradiol 0.035mg
Study NCT01129102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for NPC-01
Study NCT03871582 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Cross-sectional
Study NCT02797080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon γ-1b
Description: ACTIMMUNE® will be administered three times per week by subcutaneous injection. The initial dose will be individualized for each participant and will be determined by the investigator, provided that the initial dose does not exceed the maximum tolerated dose in HZNP-ACT-302 (NCT02593773). The investigator may subsequently adjust the dose for any participant if deemed clinically appropriate, provided that the dose does not exceed 100 μg/m².
Study NCT00951015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: investigational HIV-1 integrase inhibitor
Study NCT00951015 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: efavirenz
Description: approved therapy for HIV-1 infection, used as an internal study control
Study NCT03912051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: asymmetric balloon
Description: Asymmetric balloon for treatment of intranasal bleeding
Study NCT02683785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165
Description: GSK3196165 will be supplied as a liquid and will be administered as a subcutaneous injection. The drug will be administered weekly for 5 injections, then every other week for 3 further injections.
Study NCT02799147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Study NCT02683785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as above.
Study NCT05976373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab (SAR231893)
Description: injection solution subcutaneous
Study NCT05976373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab (SAR231893)
Description: injection solution subcutaneous
Study NCT03250442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PrevenaTM Device
Description: The PrevenaTM Incision Management System covers and protects the incision from external contamination, while negative pressure removes fluid and infectious material from the surgical incision.
Study NCT03250442 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Dry Dressing
Description: These are customary dry dressings.
Study NCT03423576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive patient-centered outpatient health service with multiple components
Description: Individualized multi-component education and counselling program coordinated by a case Manager.
Study NCT01401153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skipping lunch
Description: Just water.
Study NCT02243670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AiCure monitoring and intervention
Description: Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®. If a participant misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by research staff or the AiCure study team through automated SMS text or by phone.